NGeneBio

엔젠바이오 · 354200

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$19.7M (₩27.1B)

Overview

NGeneBio develops diagnostic tools and software that analyse a person's genetic information to help identify diseases, using a technology called next-generation sequencing (NGS), which reads DNA rapidly and at scale.

Its products and services are used in medical and research settings, and it also supplies medical-grade software and databases. Listed on KOSDAQ, South Korea's tech-focused small-cap exchange, the company has been broadening its registered business scope to include healthcare product distribution, logistics services to hospitals and pharmacies, and medical-device e-commerce.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$15.4M

▲ +273.2% YoY

Operating profit · FY2025

−US$6M

Loss narrowed

Net income · FY2025

−US$4.9M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$3.2M(₩4.4B)	US$4.1M(₩5.7B)	US$15.4M(₩21.2B)
Operating profit	−US$9.7M(−₩13.4B)	−US$11.6M(−₩16.1B)	−US$6M(−₩8.3B)
Net income	−US$9.3M(−₩12.9B)	−US$10.1M(−₩13.9B)	−US$4.9M(−₩6.8B)

Revenue

FY2023US$3.2M
FY2024US$4.1M
FY2025US$15.4M

Operating profit

FY2023−US$9.7M
FY2024−US$11.6M
FY2025−US$6M

Net income

FY2023−US$9.3M
FY2024−US$10.1M
FY2025−US$4.9M

Key ratios (FY2025)

ROE

-29.9%

Debt/Eq

220.2%

Op. margin

-39.0%

Net margin

-31.8%

Rev. YoY

▲ +273.2%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?